These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29558014)

  • 21. [Osimertinib (Tagrisso
    Giroux Leprieur E; Cortot AB; Cadranel J; Wislez M
    Bull Cancer; 2016 Oct; 103(10):815-821. PubMed ID: 27641462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
    Taus Á
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Girard N
    Future Oncol; 2018 May; 14(11):1117-1132. PubMed ID: 29336166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
    Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
    J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
    Ke EE; Wu YL
    Ther Adv Respir Dis; 2016 Jun; 10(3):256-64. PubMed ID: 26929305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osimertinib for the treatment of patients with
    Alsharedi M; Bukamur H; Elhamdani A
    Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
    Garfield D
    J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W; Tufman A; Huber RM
    Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
    Nishino K; Imamura F; Morita S; Mori M; Komuta K; Kijima T; Namba Y; Kumagai T; Yamamoto S; Tachibana I; Nakazawa Y; Uchida J; Minami S; Takahashi R; Yano Y; Okuyama T; Kumanogoh A
    Lung Cancer; 2013 Nov; 82(2):299-304. PubMed ID: 24018023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
    Stratmann JA; Michels S; Hornetz S; Christoph DC; Sackmann S; Spengler W; Bischoff H; Schäfer M; Alt J; Müller A; Laack E; Kimmich M; Griesinger F; Sebastian M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2457-2463. PubMed ID: 30244389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary fibrosis in a patient treated with erlotinib.
    Bach JP; Kiessling AM; Kleinhans A; Faoro C; Gorg C; Riera-Knorrenschild J; Schwella N; Wagner HJ; Neubauer A
    Onkologie; 2006 Jul; 29(7):342-3. PubMed ID: 16874020
    [No Abstract]   [Full Text] [Related]  

  • 35. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
    Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
    Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
    Ogata H; Yamamoto Y; Harada T; Nakanishi Y; Okamoto I; Iwama E; Kato K; Oda Y
    J Thorac Oncol; 2017 May; 12(5):e46-e47. PubMed ID: 28434513
    [No Abstract]   [Full Text] [Related]  

  • 38. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
    Fujita K; Hirose T; Kusumoto S; Sugiyama T; Shirai T; Nakashima M; Akiyama Y; Sasaki Y
    Lung Cancer; 2014 Oct; 86(1):113-4. PubMed ID: 25123334
    [No Abstract]   [Full Text] [Related]  

  • 40. Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
    Laterza MM; Chiurazzi B; Brangi M; Riccardi F; Cartenì G
    Tumori; 2013; 99(1):3e-5e. PubMed ID: 23549019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.